Theranostics utilizing radiopharmaceuticals has been experiencing high momentum owing to the advent of precision medicine as a key aspect of contemporary oncology practice.
Theranostics incorporates diagnostic imaging with treatment through the use of radiopharmaceuticals that aid medical practitioners in detecting diseases at the molecular level and provide a customized therapy approach.
There is rising incidence of certain forms of cancers including prostate cancers and NETs. Radiopharmaceuticals like Lutetium-177 (Lu-177) and Gallium-68 (Ga-68) have seen high uptake in clinical practices due to their ability to help in targeting. Clinical trials, increased regulatory approvals, and nuclear medicine infrastructure development are some of the factors driving the acceptance of radiopharmaceuticals.
The Radiopharmaceutical Theranostics Market was valued at USD 2.42 billion in 2025 and is expected to reach USD 6.93 billion by 2035, growing at a CAGR of 11.14% during 2026–2035.
Leading Radiopharmaceutical Theranostics Companies Driving Market Competition
Novartis AG
Novartis is one of the major companies in the field of radiopharmaceuticals, which specializes in the development of targeted drugs for the treatment of cancers. This company concentrates on the development of precision oncology via the implementation of innovative theranostic products. Investments in nuclear medicine and radioligand drugs help to increase the competitiveness of Novartis in the international market. This company continues to develop its clinical pipeline in oncology-based radiopharmaceuticals. It pays attention to strategic cooperation that contributes to accelerating innovation in personalized medicine.
Bayer AG
Bayer AG is another important organization in oncology and radiopharmaceutical industry. It specializes in the development of targeted therapies. This organization aims to broaden its portfolio of precision medicine in order to cover complicated cancers. Its experience in the field of life sciences contributes to constant innovation in diagnostics and therapy of various diseases. This company invests in next-generation oncology platforms and tries to reinforce its leadership in molecular imaging and theranostics.
GE HealthCare
GE HealthCare provides high-quality solutions for diagnostic imaging and nuclear medicine. This company offers innovative solutions for applying radiopharmaceuticals by means of imaging devices. These innovations contribute to the precise detection and management of cancer progression. GE HealthCare constantly implements innovations in hybrid imaging.
Bracco Imaging S.p.A.
Bracco Imaging deals mainly with diagnostic imaging agents and nuclear medicine solutions. Bracco Imaging's main focus is to create advanced radiopharmaceutical molecules for medical purposes. It offers a variety of products to increase the accuracy of diagnostics in the area of oncology. The firm is constantly doing research for future imaging agents.
Curium Pharma
Curium Pharma is one of the most prominent companies in the world when it comes to nuclear medicine and radiopharmaceutical products. Curium deals with the production of diagnostic and therapeutic radioactive molecules that are being used in the field of oncology. The firm has a strong manufacturing ability and, therefore, is capable of supplying the whole globe with its products. Moreover, it is constantly expanding its theranostics product range.
Lantheus Holdings, Inc
Lantheus Holdings manufactures diagnostic imaging agents and radiopharmaceutical products. The firm's main concern is to improve the detection and monitoring of cancer. Lantheus holds a wide range of products that contribute to precision medicine in the area of oncology.
Telix Pharmaceuticals Limited
Telix Pharmaceuticals has dedicated itself to developing innovative radiopharmaceuticals that are specifically aimed at the detection and treatment of cancer diseases. Innovation in molecular imaging and precision oncology are among the core competencies of this organization. Its product pipeline comprises novel theranostics in various cancer fields. Telix Pharmaceuticals continues growing its clinical portfolio internationally.
Industry Trends Supporting Growth
Increasing incidences of cancers like prostate cancer and neuroendocrine tumors represent one of the main factors driving the growth of the market for theranostics utilizing radiopharmaceuticals. The nature of these diseases requires precise and individualized therapeutic approaches that are achievable using theranostics through imaging and therapy at the molecular level.
Adoption of Lu-177 and Ga-68 radiopharmaceuticals is another key factor boosting the demand for theranostic solutions in the market. As these medicines help achieve enhanced accuracy in diagnostics and therapeutic procedures, more and more oncologists tend to prescribe radiopharmaceuticals to patients.
Growth in clinical support for the efficacy of theranostics also boosts the adoption rates of these treatments. Apart from this, favorable regulations and rising awareness among clinicians are expected to lead to an increased adoption rate of radiopharmaceutical theranostics among healthcare providers.
Expansion of infrastructure related to nuclear medicine and investments made in precision oncology also positively influence the market. There has been an increase in the adoption of imaging and precise therapy options by healthcare systems to enhance the diagnostic process in cancer cases.
Will Radiopharmaceutical Theranostics Continue to Transform Cancer Care?
The future prospects of the market are likely to be bright because of the adoption of precision oncology in clinical practices, whereby companies will invest in developing a pipeline of products, enhancing their capability to produce isotopes, and conducting clinical studies of radiation therapies.
The increasing adoption of personalized medicine, the rising burden of cancer, and the constant advancement in nuclear medicine indicate that theranostics would soon become an essential aspect of cancer treatment approaches.
Radiopharmaceuticals and their use in diagnosing and treating cancer will revolutionize how cancer is treated. There is a possibility that the market may experience high growth in future because of the promising developments in clinical adoption and technologies.
